Health Awareness
Aussies need a nationally consistent vaccination approach
Following a decline in vaccination rates following the peak of the COVID-19 pandemic, a new report is calling for a united, consistent, national approach to vaccinate Australians following a decline in vaccination rates after the peak of the COVID-19 pandemic. The Grattan Institute’s ‘A fair shot: How to close the vaccination gap’ report suggests taking…
Read MoreCelebrating 30 years of the ‘JDRF One Walk’ for Type 1 diabetes
This October 2023, the Juvenile Diabetes Foundation (JDRF) is celebrating 30 years of running the JDRF local One Walk. Striving to achieve a world free from Type 1 diabetes (T1D) courtesy of crucial, life-changing research, the JDRF One Walk event provides invaluable support to the T1D community, including the more than 130,000 Australians living with…
Read MoreToday is World Tuberculosis Day
On this day (Friday, March 24) in 1882, Dr. Robert Koch discovered the bacterium that causes tuberculosis (TB), pioneering the path towards a TB-free world. Nowadays, we band together every year on this date to raise awareness of TB, the leading cause of death by infectious disease worldwide. In 2021 alone, TB infected 10.6 million…
Read MoreVIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards
VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma, and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel. Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…
Read More
First treatment in 10 years PBS listed for Aussies
living with aggressive stomach & oesophageal cancers
Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…
Read More